Xenetic Biosciences Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 2

Employees

  • Stock Symbol
  • XBIO

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $1.66
  • (As of Thursday Closing)

Xenetic Biosciences General Information

Description

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.

Contact Information

Website
www.xeneticbio.com
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 945 Concord Street
  • Framingham, MA 01701
  • United States
+1 (781)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 945 Concord Street
  • Framingham, MA 01701
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xenetic Biosciences Stock Performance

As of 12-Nov-2026, Xenetic Biosciences’s stock price is $1.66. Its current market cap is $3.89M with 2.34M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.66 $1.87 $1.58 - $4.94 $3.89M 2.34M 74.4K -$1.15

Xenetic Biosciences Financials Summary

As of 30-Jun-2026, Xenetic Biosciences has a trailing 12-month revenue of $3.26M.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (679) 852 (685) (4,458)
Revenue 3,261 2,976 2,500 2,540
EBITDA (2,637) (2,829) (4,210) (4,490)
Net Income (2,475) (2,681) (3,960) (4,135)
Total Assets 6,968 8,364 6,901 10,605
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Xenetic Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Xenetic Biosciences‘s full profile, request access.

Request a free trial

Xenetic Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing diff
Drug Discovery
Framingham, MA
2 As of 2025

Wilmington, DE
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xenetic Biosciences Competitors (62)

One of Xenetic Biosciences’s 62 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ayala Pharmaceuticals Corporation Wilmington, DE
Elicio Therapeutics Formerly VC-backed Boston, MA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Protagonist Therapeutics Formerly VC-backed Newark, CA
Oncorus Formerly VC-backed Andover, MA
You’re viewing 5 of 62 competitors. Get the full list »

Xenetic Biosciences Patents

  • 13

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

Xenetic Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4486370-A1 Chimeric antigen receptor t-cell treatments targeted to chromatin fragments and extracellular traps Pending 01-Mar-2022
GB-202202842-D0 Chimeric antigen receptor t-cell treatments targeted to chromatin fragments and extracellular traps Inactive 01-Mar-2022
US-20250170241-A1 Chimeric antigen receptor t-cell treatments targeted to chromatin fragments and extracellular traps Pending 01-Mar-2022
WO-2023166087-A1 Chimeric antigen receptor t-cell treatments targeted to chromatin fragments and extracellular traps Inactive 01-Mar-2022
AU-2020219736-A1 Methods of using glycopolysialylated therapeutic proteins Inactive 04-Feb-2019 A61K47/61
To view Xenetic Biosciences’s complete patent history, request access »

Xenetic Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xenetic Biosciences Investments & Acquisitions (4)

Xenetic Biosciences’s most recent deal was a Reverse Merger with Santersus. The deal was made on 16-Sep-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Santersus 16-Sep-2026 Reverse Merger Therapeutic Devices
XCART Platform 04-Mar-2019 Corporate Asset Purchase Buildings and Property
General Sales and Leasing 23-Jan-2014 Merger/Acquisition Media and Information Services (B2B)
SymbioTec (Germany) 17-Jan-2012 Merger/Acquisition Drug Discovery
To view Xenetic Biosciences’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

Xenetic Biosciences ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Xenetic Biosciences’s complete esg history, request access »

Xenetic Biosciences FAQs

  • When was Xenetic Biosciences founded?

    Xenetic Biosciences was founded in 2011.

  • Where is Xenetic Biosciences headquartered?

    Xenetic Biosciences is headquartered in Framingham, MA.

  • What is the size of Xenetic Biosciences?

    Xenetic Biosciences has 2 total employees.

  • What industry is Xenetic Biosciences in?

    Xenetic Biosciences’s primary industry is Drug Discovery.

  • Is Xenetic Biosciences a private or public company?

    Xenetic Biosciences is a Public company.

  • What is Xenetic Biosciences’s stock symbol?

    The ticker symbol for Xenetic Biosciences is XBIO.

  • What is the current stock price of Xenetic Biosciences?

    As of 12-Nov-2026 the stock price of Xenetic Biosciences is $1.66.

  • What is the current market cap of Xenetic Biosciences?

    The current market capitalization of Xenetic Biosciences is $3.89M.

  • What is Xenetic Biosciences’s current revenue?

    The trailing twelve month revenue for Xenetic Biosciences is $3.26M.

  • Who are Xenetic Biosciences’s competitors?

    Ayala Pharmaceuticals, Elicio Therapeutics, CytomX Therapeutics, Protagonist Therapeutics, and Oncorus are some of the 62 competitors of Xenetic Biosciences.

  • What is Xenetic Biosciences’s annual earnings per share (EPS)?

    Xenetic Biosciences’s EPS for 12 months was -$1.15.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process